COVID-19 UPDATE

Contact

BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

Events & Presentations

Past Events

Cantor Fitzgerald Global Healthcare Conference

Sep 17, 2020 at 11:20 AM EDT

Listen to webcast

H.C. Wainwright 22nd Annual Global Investor Conference

Sep 14, 2020 at 12:30 PM EDT

Listen to webcast

September Investor Presentation

Sep 9, 2020

Supporting Materials

View Presentation 1 MB

BDSI Second Quarter 2020 Financial Results Call and Webcast

Aug 5, 2020 at 8:30 AM EDT

Listen to webcast

Supporting Materials

View Presentation 662.8 KB

William Blair 40th Annual Growth Stock Conference

Jun 11, 2020 at 9:40 AM EDT

Listen to webcast

Jefferies Virtual Healthcare Conference

Jun 2, 2020 at 3:00 PM EDT

Listen to webcast

Supporting Materials

View Presentation 1.3 MB

BDSI First Quarter 2020 Financial Results Call and Webcast

May 7, 2020 at 4:30 PM EDT

Listen to webcast

Supporting Materials

View Presentation 586.1 KB

BDSI Fourth Quarter 2019 Financial Results Call and Webcast

Mar 12, 2020 at 4:30 PM EDT

Listen to webcast

Supporting Materials

View Presentation 603.9 KB

Piper Jaffray 31st Annual Healthcare Conference

Dec 4, 2019 at 12:00 PM EST

Recent BDSI News

BioDelivery Sciences Announces Five Scientific Poster Presentations at PAINWeek® 2020 National Conference on Pain Management September 11, 2020

New Scientific Information Further Highlights Differentiated Clinical Profile of BELBUCA® (buprenorphine buccal film) RALEIGH, N.C. , Sept. 11, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients ...

BioDelivery Sciences to Present at Two Upcoming Investor Conferences September 3, 2020

RALEIGH, N.C. , Sept. 03, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey Bailey , Interim Chief Executive ...

BioDelivery Sciences Reports Strong Q2 2020 Results August 5, 2020

Second Quarter Total Company Net Revenue Increased 23% versus Prior Year to $36.6 Million Second Quarter BELBUCA® Net Sales Increased 34% versus Prior Year to $32.3 Million BELBUCA and Symproic® Each Reach All Time High TRx Volume and Market Share Conference Call and Webcast Scheduled for 8:30 AM ...

More news

More events

Stay Connected

Stay up to date on the latest news

Get started now